NEW PHARMACOLOGICAL TOOLS FOR ALPHA ADRENERGIC RECEPTORS

Information

  • Research Project
  • 2272230
  • ApplicationId
    2272230
  • Core Project Number
    R43NS033418
  • Full Project Number
    1R43NS033418-01
  • Serial Number
    33418
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/1994 - 30 years ago
  • Project End Date
    3/14/1995 - 29 years ago
  • Program Officer Name
  • Budget Start Date
    9/15/1994 - 30 years ago
  • Budget End Date
    3/14/1995 - 29 years ago
  • Fiscal Year
    1994
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/9/1994 - 30 years ago

NEW PHARMACOLOGICAL TOOLS FOR ALPHA ADRENERGIC RECEPTORS

Alpha adrenoceptors serve numerous functions throughout the peripheral and central nervous systems. Chemical modulators of these receptors have a variety of potential therapeutic applications, including treatments for benign prostatic hyperplasia, hypertension, pain and glaucoma. Although six alpha adrenoceptor subtypes are now known, little information is available concerning the locations and physiological functions of these subtypes in the body. The three-dimensional structures of these receptors, and the chemical nature of their interactions with ligands are also poorly understood. Ligands were identified by our cloned human receptor screening program which bind selectively to individual alpha adrenoceptor subtypes. In Phase I, some of these compounds will be used as templates for the design of new pharmacological tools. These tools will include molecules that selectively inactivate one subtype by covalent modification, as well as subtype-selective radioligands. In Phase I and II, these new pharmacological tools will be used to determine the localization and functional capabilities of the different alpha adrenergic subtypes in various human and animal tissues. These tools will also be useful for structural characterization of the receptor-ligand complexes. Information obtained in these studies will aid the identification of new therapeutic opportunities and the design of new drugs.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R43
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    SYNAPTIC PHARMACEUTICAL CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    PARAMUS
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    07652
  • Organization District
    UNITED STATES